The drug-resistant mpox cases follow an initial, unrelated cluster reported in California in late 2022-early 2023, and are the first involving multiple states, according to the report.

During the study period, a total of 81 case patients from 18 states were identified. Of these cases, 27 were identified through surveillance cultures, and 54 were identified through clinical cultures.